⏰ TL;DR (Too Long; Didn't Read)

💡The Idea

• Magnetic Resonance Spectroscopy (MRS) is an advanced MRI technique that provides a non-invasive, real-time biochemical snapshot of cellular activity. It's used for diagnosing and monitoring various conditions, including brain tumors, dementia, stroke, and pediatric hypoxia
• Currently, MRS data analysis requires the attention and time of multiple MR physicists, limiting its widespread use in clinical settings. This is exacerbated by a global shortage of MRS experts , restricting access to this valuable diagnostic tool.
• METLiT developed AI-powered software for automating MRS data analysis, providing faster and more accurate results.

🥇Benefits

• Reduces analysis time from tens of minutes to 30 seconds
• Increases the number of detectable metabolites (17 vs. 5 in conventional methods)
• Improves accuracy compared to expert human analysis
• Enables wider adoption of MRS in clinical settings
• Provides consistent results even with lower quality data or shorter scan times

💵Business Model

• MRS Analytics (SaaS):
• Cloud-based software for hospitals and research institutions
• Subscription model: $1,750 - $3,000 per month
• MRS Research:
• Consulting and data analysis services for pharma/biotech companies and academic researchers
• Fee per data: $100 - $300 (compared to $550 - $1,450 for conventional methods)
• MRS Diagnostics (In development):
• Focus on early diagnosis of dementia, particularly Normal Pressure Hydrocephalus (NPH)
• Potential for reimbursement: $52 - $1,000 per analysis

🌎Market data

• Globally, over 55 million people were living with dementia in 2020, expected to reach 78 million by 2030 and 139 million by 2050. (Alzint)
• Potential market size based on business model
• Korea: 105,000 new dementia patients annually ($32M potential market)
• Global (North America, Europe, Japan, Australia): 1,420,000 new dementia patients annually ($1B potential market)
• Broader applications in brain tumor diagnosis, dementia differential diagnosis, and other neurological conditions can increase TAM

🚀Status

• In MVP stage for MRS Analytics cloud version
• Ongoing research collaborations
• Singapore: National University Hospital (negotiating terms)
• Italy: ReGal cohort study
• Malaysia: MCI-AD study
• Preliminary clinical trials for NPH and Parkinson's disease with Seoul National University Bundang Hospital
• Patents in process in Korea, Japan, USA, and EU
• Key advisors onboarded, including Prof. Hyeonjin Kim (Seoul National University Hospital) and Prof. Jeong Hoon Lim (National University Hospital Singapore)

📋Regulation

• In process for classification as Software as Medical Device

📣Promotional materials